Share This:
https://ntp.niehs.nih.gov/go/19212

TDMS Study 96022-02 Pathology Tables

NTP Experiment-Test: 96022-02  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                            TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118)                       Date: 04/27/04
Route: GAVAGE                                                                                                     Time: 13:33:00

                                                      53 WEEK SSAC/FINAL#1




       Facility:  Battelle Columbus Laboratory

       Chemical CAS #:  TEFPCBMIX

       Lock Date:  11/04/02

       Cage Range:  All

       Reasons For Removal:    25017 Scheduled Sacrifice

       Removal Date Range:     10/12/00 - 10/13/00

       Treatment Groups:       Include 001    0 NG /  0 UG
                               Include 002    80 NG  /10 UG
                               Include 003    240 NG /30 UG
                               Include 004    800 NG /100 UG
                               Include 005    2400 NG/300 UG
                               Include 006    4000 NG/500 UG





























a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 96022-02  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                            TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118)                       Date: 04/27/04  
Route: GAVAGE                                                                                                     Time: 13:33:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       80 NG  /     240 NG /     800 NG /     2400 NG/     4000 NG/        
                                                   0 UG         10 UG        30 UG        100 UG       300 UG       500 UG          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          98           86           98           86           98           86           
                                                                                                                                    
  Scheduled Sacrifice                                 13           12           13           13           13                        
  Early Deaths                                                                                                                      
  Survivors                                                                                                                         
                                                                                                                                    
  Animals Examined Microscopically                     8            7            8            8            8                        
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Medulla                                    (8)                       (1)                       (8)                       
      Pheochromocytoma Benign                                                    1 (100%)                                           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Uterus                                             (8)          (7)          (8)          (8)          (8)                       
      Polyp Stromal, Multiple                                                                              1 (13%)                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   2                                                               
                                                                                                                                   
NTP Experiment-Test: 96022-02  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                            TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118)                       Date: 04/27/04  
Route: GAVAGE                                                                                                     Time: 13:33:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       80 NG  /     240 NG /     800 NG /     2400 NG/     4000 NG/        
                                                   0 UG         10 UG        30 UG        100 UG       300 UG       500 UG          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Mammary Gland                                      (8)          (2)          (1)          (1)          (8)                       
      Fibroadenoma                                                  1 (50%)      1 (100%)     1 (100%)     1 (13%)                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (8)          (7)          (8)          (8)          (8)                       
      Cystic Keratinizing Epithelioma                                                                      4 (50%)                  
      Cystic Keratinizing Epithelioma, Multiple                                               1 (13%)      1 (13%)                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   3                                                               
                                                                                                                                   
NTP Experiment-Test: 96022-02  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                            TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118)                       Date: 04/27/04  
Route: GAVAGE                                                                                                     Time: 13:33:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       80 NG  /     240 NG /     800 NG /     2400 NG/     4000 NG/        
                                                   0 UG         10 UG        30 UG        100 UG       300 UG       500 UG          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)                         1           2           2           5                           
     Total Primary Neoplasms                                        1           2           2           7                           
                                                                                                                                    
   Total Animals with Benign Neoplasms                              1           2           2           5                           
     Total Benign Neoplasms                                         1           2           2           7                           
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
     Total Malignant Neoplasms                                                                                                      
                                                                                                                                    
   Total Animals with Metastatic Neoplasms                                                                                          
     Total Metastatic Neoplasm                                                                                                      
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   4                                                               
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------